Quick Comparison
| BPC-157 | Livagen | |
|---|---|---|
| Half-Life | 4 hours (stable in gastric juice) | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Standard: 200-800 mcg subcutaneous once daily, or 500-1000 mcg oral once daily. Often cycled 4-6 weeks on, 2 weeks off. Injectable may be administered near the injury site for localized healing. Oral route used primarily for gut-related conditions. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling rather than continuous use. |
| Administration | Subcutaneous injection, intramuscular injection, or oral | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 30 papers | 5 papers |
| Categories |
Mechanism of Action
BPC-157
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Its mechanism of action is remarkably multifaceted, affecting multiple organ systems and healing pathways simultaneously, which is unusual for a single peptide. The primary mechanism centers on the nitric oxide (NO) system — BPC-157 modulates both constitutive (eNOS) and inducible (iNOS) nitric oxide synthase, and can either promote or inhibit NO production depending on the tissue context and injury state.
BPC-157's regenerative effects are mediated through upregulation of multiple growth factors. It increases expression of vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels at injury sites, which is critical for delivering oxygen and nutrients for tissue repair. It also upregulates epidermal growth factor (EGF), nerve growth factor (NGF), and hepatocyte growth factor (HGF) receptors, supporting wound healing, nerve regeneration, and organ protection respectively. In tendon and ligament injuries, BPC-157 stimulates fibroblast migration and proliferation, accelerating collagen deposition and organized tissue repair rather than scar formation.
Beyond structural healing, BPC-157 has significant effects on the central and enteric nervous systems. It modulates dopaminergic, serotonergic, GABAergic, and opioid systems, which may explain reported effects on mood, gut function, and pain perception. It protects endothelial function, counteracts the effects of NSAIDs on the gastric mucosa, and has demonstrated cytoprotective effects in models of liver, brain, heart, and intestinal damage. The peptide also interacts with the FAK-paxillin pathway, which is central to cell adhesion and migration during wound healing. Its stability in gastric juice — unusual for a peptide — enables oral administration, making it one of the few peptides effective by both injectable and oral routes.
Livagen
Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.
Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.
As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.
Risks & Safety
BPC-157
Common
nausea, dizziness, mild headache, injection site irritation.
Serious
no completed human studies, so long-term effects are unestablished.
Rare
allergic reactions, theoretical concern about promoting new blood vessel growth in existing tumors.
Livagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; long-term safety in the context of pre-existing liver disease is not established.
Rare
allergic reactions. Like other Khavinson bioregulators, the evidence base is significantly thinner than the marketing suggests.
Full Profiles
BPC-157 →
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
Livagen →
A Khavinson tripeptide (Lys-Glu-Asp) developed in Russia as a tissue-specific bioregulator targeting the liver. Promoted for supporting liver regeneration, age-related liver decline, and as part of broader anti-ageing protocols. Sits in the same family as epithalon (pineal), cortagen (brain), and pinealon (pineal/brain). Most evidence is from Russian preclinical work — rigorous Western clinical trials are essentially nonexistent.